Evidence map›Paper›PMID 35747160›Full record

ArticleEClinicalMedicine2022

Neurodevelopmental and growth outcomes after invasive Group B

Proma Paul, Jaya Chandna, Simon R Procter, Ziyaad Dangor, Shannon Leahy, Sridhar Santhanam, Hima B John, Quique Bassat, Justina Bramugy, Azucena Bardají and 14 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in EClinicalMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06833957 (PReparing for OptimalPhase III/IV maTErnal Group B StreptococCal Vaccine Trials in Africa), which is not on this map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06833957 recruitingnot on this mapstarted 2025, after this paper: background citation

PReparing for OptimalPhase III/IV maTErnal Group B StreptococCal Vaccine Trials in Africa (PROTECT)

Typeobservational_patient_registrySponsorBarcelona Institute for Global HealthRan2025 to 2027Enrolled18,100ConditionsGroup B Streptococcus, Invasive Bacterial Diseases (IBD), Maternal Immunization
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Maternal Group BClinical epidemiology · 2026
    Article
  5. Review
  6. Group BLancet regional health. Americas · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 10 institutions in 10 countries.

Proma PaulDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Jaya ChandnaDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Simon R ProcterDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Ziyaad DangorMedical Research Council: Vaccines and Infectious Diseases Analytical Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Shannon LeahyDepartment of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Sridhar SanthanamNeonatology Department, Christian Medical College, Vellore, India.
Hima B JohnNeonatology Department, Christian Medical College, Vellore, India.
Quique BassatCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Justina BramugyCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Azucena BardajíCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Amina AbubakarNeuroscience Research Group, Department of Clinical Sciences, KEMRI-Wellcome Trust, Kilifi, Kenya.
Carophine NasambuNeuroscience Research Group, Department of Clinical Sciences, KEMRI-Wellcome Trust, Kilifi, Kenya.
Romina LibsterFundación INFANT, Buenos Aires, Argentina.
Clara Sánchez YanottiFundación INFANT, Buenos Aires, Argentina.
Farah SeedatDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Erzsébet Horváth-PuhóDepartment of Clinical Epidemiology, Aarhus University, Aarhus N, Denmark.
A K M Tanvir HossainMaternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Qazi Sadeq-Ur RahmanMaternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Mark JitDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Charles R NewtonNeuroscience Research Group, Department of Clinical Sciences, KEMRI-Wellcome Trust, Kilifi, Kenya.
Kate MilnerNeurodisability & Rehabilitation Research Group, Murdoch Children's Research Institute.
Bronner P GonçalvesDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Joy E LawnDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
GBS long term outcomes LMIC collaborative group
Kenya Medical Research Institute · KELondon School of Hygiene & Tropical Medicine · GBChristian Medical College, Vellore · INInternational Centre for Diarrhoeal Disease Research · BDUniversity of the Witwatersrand · ZAInfant Foundation · ARInstitució Catalana de Recerca i Estudis Avançats · ESManhiça Health Research Centre · MZAarhus University · DKThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Data are limited regarding long-term consequences of invasive GBS (iGBS) disease in early infancy, especially from low- and middle-income countries (LMIC) where most cases occur. We aimed to estimate risk of neurodevelopmental impairment (NDI) in children with a history of iGBS disease. Methods: A multi-country matched cohort study was undertaken in South Africa, India, Mozambique, Kenya, and Argentina from October 2019 to April 2021. The exposure of interest was defined as a history of iGBS disease (sepsis or meningitis) before 90 days of age, amongst children now aged 1·5-18 years. Age and sex-matched, children without history of GBS were also recruited. Age-appropriate, culturally-adapted assessments were used to define NDI across multiple domains (cognitive, motor, hearing, vision, emotional-behaviour, growth). Pooled NDI risk was meta-analysed across sites. Association of iGBS exposure and NDI outcome was estimated using modified Poisson regression with robust variance estimator. Findings: Amongst 138 iGBS survivors and 390 non-iGBS children, 38·1% (95% confidence interval [CI]: 30·0% - 46·6%) of iGBS children had any NDI, compared to 21·7% (95% CI: 17·7% - 26·0%) of non- iGBS children, with notable between-site heterogeneity. Risk of moderate/severe NDI was 15·0% (95% CI: 3·4% - 30·8%) among GBS-meningitis, 5·6% (95% CI: 1·5% - 13·7%) for GBS-sepsis survivors. The adjusted risk ratio (aRR) for moderate/severe NDI among iGBS survivors was 1.27 (95% CI: 0.65, 2.45), when compared to non-GBS children. Mild impairment was more frequent in iGBS (27.6% (95% CI: 20.3 - 35.5%)) compared to non-GBS children (12.9% (95% CI: 9.7% - 16.4%)). The risk of emotional-behavioural problems was similar irrespective of iGBS exposure (aRR=0.98 (95% CI: 0.55, 1.77)). Interpretation: Our findings suggest that iGBS disease is on average associated with a higher risk of moderate/severe NDI, however substantial variation in risk was observed between sites and data are consistent with a wide range of values. Our study underlines the importance of long-term follow-up for at-risk neonates and more feasible, standardised assessments to facilitate diagnosis in research and clinical practice. Funding: This work was supported by a grant (INV-009018) from the Bill & Melinda Gates Foundation to the London School of Hygiene &Tropical Medicine.

Indexed as

childrenDisabilityGroup B streptococcusImpairmentInfantsMeningitisNeurodevelopmentSepsis

Identifiers

PMID35747160
PMCPMC9142788
OpenAlexW4224985376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.